文献速递临床试验与 GCP真实世界研究与卫生经济

DISC试验:杜普伊特伦挛缩手术与胶原酶注射的随机对照研究方案

Dupuytren's interventions surgery versus collagenase (DISC) trial: study protocol for a pragmatic, two-arm parallel-group, non-inferiority randomised controlled trial.
PubMed 文献 · Trials · 2021-09-30

DISC试验是一项多中心、实用型、双臂平行组、非劣效性随机对照试验,计划纳入710例成人杜普伊特伦挛缩患者,按1:1随机接受胶原酶注射或限制性筋膜切除术。主要结局为治疗后1年患者自评评估量表,旨在比较两种治疗的临床与成本效果,填补胶原酶与手术对比的证据空白。

要点

  • 首个对比胶原酶与限制性筋膜切除术的随机对照试验,计划纳入710例成人患者。
  • 主要结局为治疗后1年患者自评评估量表(PEM),并评估成本效果与患者体验。
  • 次要结局包括复发、并发症、功能恢复时间及多种手功能与生活质量量表。

核心结论

  • DISC试验旨在填补胶原酶与限制性筋膜切除术临床有效性对比缺乏稳健随机对照试验的证据空白。

研究设计与样本

  • 多中心实用型双臂平行组随机对照试验,参与者按1:1分配接受胶原酶注射或限制性筋膜切除术。
  • 计划招募710例成人杜普伊特伦挛缩患者,从初级和二级医疗机构识别,由授权临床医生筛查。

关键数值与推荐

  • 主要结局为治疗后1年自报的患者评估量表(PEM)。
  • 次要结局包括Unité Rhumatologique des Affections de la Main量表、密歇根手问卷、EQ-5D-5L、资源使用、进一步手术、并发症、复发、总主动活动度与伸展缺陷及恢复功能时间。

临床怎么用

  • 试验结果将为杜普伊特伦挛缩患者在胶原酶注射与限制性筋膜切除术之间的选择提供临床与成本效果证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dupuytren's contracture is a fibro-proliferative disease of the hands affecting over 2 million UK adults, particularly the white, male population. Surgery is the traditional treatment; however, recent studies have indicated that an alternative to surgery-collagenase clostridium histolyticum (collagenase)-is better than a placebo in the treatment of Dupuytren's contracture. There is however no robust randomised controlled trial that provides a definitive answer on the clinical effectiveness of collagenase compared with limited fasciectomy surgery. Dupuytren's intervention surgery vs collagenase trial (DISC) trial was therefore designed to fill this evidence gap. METHODS/DESIGN: The DISC trial is a multi-centre pragmatic two-arm parallel-group, randomised controlled trial. Participants will be assigned 1:1 to receive either collagenase injection or surgery (limited fasciectomy). We aim to recruit 710 adult participants with Dupuytren's contracture. Potential participants will be identified in primary and secondary care, screened by a delegated clinician and if eligible and consenting, baseline data will be collected and randomisation completed. The primary outcome will be the self-reported patient evaluation measure assessed 1 year after treatment. Secondary outcome measures include the Unité Rhumatologique des Affections de la Main Scale, the Michigan Hand Questionnaire, EQ-5D-5L, resource use, further procedures, complications, recurrence, total active movement and extension deficit, and time to return to function. Given the limited evidence comparing recurrence rates following collagenase injection and limited fasciectomy, and the importance of a return to function as soon as possible for patients, the associated measures for each will be prioritised to allow treatment effectiveness in the context of these key elements to be assessed. An economic evaluation will assess the cost-effectiveness of treatments, and a qualitative sub-study will assess participants' experiences and preferences of the treatments. DISCUSSION: The DISC trial is the first randomised controlled trial, to our knowledge, to investigate the clinical and cost-effectiveness of collagenase compared to limited fasciectomy surgery for patients with Dupuytren's contracture. TRIAL REGISTRATION: Clinical.Trials.gov ISRCTN18254597 . Registered on April 11, 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dias J, Arundel C, Tharmanathan P, et al. Dupuytren's interventions surgery versus collagenase (DISC) trial: study protocol for a pragmatic, two-arm parallel-group, non-inferiority randomised controlled trial. Trials. 2021. PMID: 34593024. doi:10.1186/s13063-021-05595-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。